Cancer Research Technology

Cancer Research Technology

And commercialises exciting new discoveries in cancer research.

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
GBP2017201820192020202120222023
Revenues0000000000000000000000000000
% growth4 %14 %22 %(7 %)(14 %)1 %(17 %)
EBITDA0000000000000000000000000000
% EBITDA margin41 %49 %32 %30 %35 %18 %23 %
Profit0000000000000000000000000000
% profit margin46 %38 %45 %32 %40 %42 %19 %
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue-3 %-----

Source: Company filings or news article

Notes (0)
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Cancer Research Technology

Edit
Spirogen
ACQUISITION by AstraZeneca Oct 2013